AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37294609 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated health promotion interventions in web-based community games
Number of subjects: 22
Study 37294671 — intervention group
Group type: EXPERIMENTAL
Intervention: Left bundle branch pacing (LBBP)
Number of subjects: 24
Study 37294671 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise application of ECG and electrogram criteria
Number of subjects: 24
Study 37294727 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercise programme (38 weeks, 2 sessions/week, 15 min/session)
Number of subjects: 103
Study 37294727 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 103
Study 37294816 — intervention group
Group type: EXPERIMENTAL
Intervention: Veterans with a lifetime history of SA
Number of subjects: 183
Study 37294816 — intervention group
Group type: COMPARATOR
Intervention: Veterans without a lifetime history of SA
Number of subjects: 183
Study 37294823 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based teach-to-go intervention
Number of subjects: 103
Study 37294843 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day treatment (same-day TB testing with same-day TB treatment if TB diagnosed; same-day ART if TB not diagnosed)
Number of subjects: 500
Study 37294843 — intervention group
Group type: COMPARATOR
Intervention: Standard care (initiating TB treatment within 7 days and delaying ART to day 7 if TB not diagnosed)
Number of subjects: 500
Study 37294870 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 277
Study 37294870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277
Study 37294870 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib (SENSCIS-ON)
Number of subjects: 277
Study 37294870 — intervention group
Group type: COMPARATOR
Intervention: Placebo (SENSCIS-ON)
Number of subjects: 277
Study 37294914 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (starting dose of 50 mg once daily to a maximum of 300 mg)
Number of subjects: 169
Study 37294914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 37294939 — intervention group
Group type: EXPERIMENTAL
Intervention: same™ device (Smart Autotransfusion for ME; i-SEP, France) used intraoperatively to treat shed and residual cardiopulmonary bypass blood.
Number of subjects: 50
Study 37294939 — intervention group
Group type: EXPERIMENTAL
Intervention: same™ device
Number of subjects: 50
Study 37294948 — intervention group
Group type: EXPERIMENTAL
Intervention: XMT-1660 (site-specific DS DAR 6 ADC)
Number of subjects: 0
Study 37294948 — intervention group
Group type: EXPERIMENTAL
Intervention: XMT-1660
Number of subjects: 0
Study 37295011 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal Expressive Skill Management Program in Urdu (VESMP-U)
Number of subjects: 54
Study 37295011 — intervention group
Group type: COMPARATOR
Intervention: Melodic Intonation Therapy (MIT)
Number of subjects: 54
Study 37295035 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutralizing antibodies (NAb) transfer ratio (TR)
Number of subjects: 173
Study 37295035 — intervention group
Group type: COMPARATOR
Intervention: Male newborns
Number of subjects: 173
Study 37295035 — intervention group
Group type: COMPARATOR
Intervention: NAb TR in 3rd trimester SARS-CoV-2 infected mothers
Number of subjects: 173
Study 37295035 — intervention group
Group type: COMPARATOR
Intervention: NAb TR in 1st or 2nd trimester infected mothers
Number of subjects: 173
Study 37295336 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone Replacement Therapy (GHRT)
Number of subjects: 7
Study 37295445 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel) at a target dose level of 50 × 10^6 cells, administered as a single intravenous infusion.
Number of subjects: 117
Study 37295445 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel)
Number of subjects: 117
Study 37295501 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program guided by the Health Promotion Model
Number of subjects: 69
Study 37295609 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Number of subjects: 0
Study 37295609 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 0
Study 37295665 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg daily for 12 weeks
Number of subjects: 21
Study 37295665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 37295667 — intervention group
Group type: EXPERIMENTAL
Intervention: LVAD implantation
Number of subjects: 22
Study 37295720 — intervention group
Group type: EXPERIMENTAL
Intervention: NK cell-enriched molecular rejection-like state (NKRL)
Number of subjects: 896
Study 37295720 — intervention group
Group type: EXPERIMENTAL
Intervention: T cell-mediated rejection (TCMR)/Mixed
Number of subjects: 896
Study 37295720 — intervention group
Group type: COMPARATOR
Intervention: No rejection
Number of subjects: 896
Study 37295793 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene block with perineural or intravenous adjuvants
Number of subjects: 477
Study 37295810 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipeline Embolization Device (PED) treatment
Number of subjects: 218
Study 37295810 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive coiling
Number of subjects: 218
Study 37295810 — intervention group
Group type: EXPERIMENTAL
Intervention: Dense embolism
Number of subjects: 218
Study 37295816 — intervention group
Group type: EXPERIMENTAL
Intervention: CD22 CAR T-cells
Number of subjects: 53
Study 37295824 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention consisting of early cooperation among GP, care manager, and rehabilitation coordinator, plus a person-centred dialogue meeting between patient and employer within 3 months.
Number of subjects: 341
Study 37295823 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for patellar instability
Number of subjects: 15
Study 37295836 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised duration of antibiotic therapy (3 days after clinical improvement)
Number of subjects: 408
Study 37295836 — intervention group
Group type: COMPARATOR
Intervention: Standard duration of antibiotic therapy (10 days)
Number of subjects: 408
Study 37296040 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate biopsy approach recommended by the European Association of Urology
Number of subjects: 0
Study 37296040 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate biopsy approach recommended by the American Urological Association
Number of subjects: 0
Study 37296040 — intervention group
Group type: COMPARATOR
Intervention: Current level 1 evidence
Number of subjects: 0
Study 37296268 — intervention group
Group type: EXPERIMENTAL
Intervention: FACIT-Fatigue
Number of subjects: 63
Study 37296409 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding
Number of subjects: 235
Study 37296409 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial breastfeeding
Number of subjects: 235
Study 37296409 — intervention group
Group type: EXPERIMENTAL
Intervention: No breastfeeding
Number of subjects: 235
Study 37296409 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparity
Number of subjects: 235
Study 37296409 — intervention group
Group type: EXPERIMENTAL
Intervention: Early breastfeeding in the first hour
Number of subjects: 235
Study 37296409 — intervention group
Group type: EXPERIMENTAL
Intervention: Rooming-in
Number of subjects: 235
Study 37296411 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary in-the-bag IOL implantation
Number of subjects: 286
Study 37296411 — intervention group
Group type: COMPARATOR
Intervention: Secondary sulcus IOL implantation
Number of subjects: 286
Study 37296413 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic exercise protocol, 3 days per week for 10 weeks
Number of subjects: 0
Study 37296432 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol and clonidine
Number of subjects: 47
Study 37296432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 37296456 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 439
Study 37296463 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Number of subjects: 75
Study 37296468 — intervention group
Group type: EXPERIMENTAL
Intervention: short, animated storytelling intervention video on sodium as a cardiovascular disease risk factor
Number of subjects: 10000
Study 37296468 — intervention group
Group type: COMPARATOR
Intervention: surveys only
Number of subjects: 10000
Study 37296468 — intervention group
Group type: COMPARATOR
Intervention: attention placebo control video
Number of subjects: 10000
Study 37296468 — intervention group
Group type: COMPARATOR
Intervention: exposed to neither the video nor the surveys
Number of subjects: 10000
Study 37296922 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin-ifosfamide chemotherapy and 5 × 5 Gy radiotherapy
Number of subjects: 19
Study 37296922 — intervention group
Group type: EXPERIMENTAL
Intervention: High expression of HIF-1α before surgery
Number of subjects: 19
Study 37296922 — intervention group
Group type: EXPERIMENTAL
Intervention: Samples after surgery with decreased expression of HIF-1α
Number of subjects: 19
Study 37296922 — intervention group
Group type: EXPERIMENTAL
Intervention: High expression of γH2AFX
Number of subjects: 19
Study 37296922 — intervention group
Group type: EXPERIMENTAL
Intervention: High number of positive-staining tumor-associated macrophages (TAMs) and high microvessel density (IMVD)
Number of subjects: 19
Study 37296982 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunal tube peptide-based diet for 12 weeks
Number of subjects: 31
Study 37296982 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil-based chemotherapy (e.g., FOLFIRINOX)
Number of subjects: 31
Study 37296982 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine-based chemotherapy (e.g., gemcitabine/nab-paclitaxel)
Number of subjects: 31
Study 37297976 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure device
Number of subjects: 0
Study 37297976 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37300312 — intervention group
Group type: EXPERIMENTAL
Intervention: Very high-frequency digital ultrasound (Insight 100)
Number of subjects: 40
Study 37300484 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine therapy for thyroid cancer
Number of subjects: 0
Study 37300573 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral hypoxia imaging
Number of subjects: 16
Study 37300632 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced envelope (padded with tracking label and colored messaging sticker)
Number of subjects: 316
Study 37300632 — intervention group
Group type: COMPARATOR
Intervention: Plain envelope
Number of subjects: 316
Study 37300632 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall clinic-level screening
Number of subjects: 316
Study 37300760 — intervention group
Group type: EXPERIMENTAL
Intervention: dupilumab + TCS
Number of subjects: 304
Study 37300760 — intervention group
Group type: COMPARATOR
Intervention: placebo + TCS
Number of subjects: 304
Study 37300792 — intervention group
Group type: EXPERIMENTAL
Intervention: GN-037 cream applied topically twice daily for 2 weeks
Number of subjects: 18
Study 37300792 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied topically twice daily for 2 weeks
Number of subjects: 18
Study 37300882 — intervention group
Group type: EXPERIMENTAL
Intervention: Early achievement of energy targets (EAET)
Number of subjects: 635
Study 37300888 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 159
Study 37300888 — intervention group
Group type: COMPARATOR
Intervention: Upfront resection (UR)
Number of subjects: 159
Study 37300888 — intervention group
Group type: COMPARATOR
Intervention: UR without adjuvant chemotherapy
Number of subjects: 159
Study 37300888 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival in NAC
Number of subjects: 159
Study 37300888 — intervention group
Group type: COMPARATOR
Intervention: Overall survival in UR
Number of subjects: 159
Study 37300888 — intervention group
Group type: COMPARATOR
Intervention: Overall survival in UR without adjuvant chemotherapy
Number of subjects: 159
Study 37301192 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia
Number of subjects: 168
Study 37301192 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 168
Study 37301468 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV ECHO (AAT to providers)
Number of subjects: 36
Study 37301468 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV ECHO+ (AAT to providers plus recall notices to vaccine-declining parents)
Number of subjects: 36
Study 37301468 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 36
Study 37301552 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraspinal muscle contraction
Number of subjects: 30
Study 37301552 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxed paraspinal muscles
Number of subjects: 30
Study 37301552 — intervention group
Group type: COMPARATOR
Intervention: 4-week no manual therapy period
Number of subjects: 30
Study 37301631 — intervention group
Group type: EXPERIMENTAL
Intervention: Zevalin (ibritumomab tiuxetan) combined with reduced intensity conditioning (RIC) regimen of fludarabine and melphalan (Flu/Mel)
Number of subjects: 41
Study 37301653 — intervention group
Group type: EXPERIMENTAL
Intervention: Rose oil aromatherapy
Number of subjects: 126
Study 37301653 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-holding
Number of subjects: 126
Study 37301653 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 126
Study 37301758 — intervention group
Group type: EXPERIMENTAL
Intervention: Copayment assistance intervention
Number of subjects: 6212
Study 37301758 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 6212
Study 37301762 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hydroxybutyrate (3-OHB)
Number of subjects: 0
Study 37301762 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin
Number of subjects: 0
Study 37301768 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive antihypertensive treatment
Number of subjects: 289
Study 37301768 — intervention group
Group type: COMPARATOR
Intervention: Standard antihypertensive treatment
Number of subjects: 289
Study 37301841 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISMS (Patient Reported Outcomes-Informed Symptom Management System)
Number of subjects: 23
Study 37301841 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 23
Study 37301885 — intervention group
Group type: EXPERIMENTAL
Intervention: Neo-T therapy with lymphodepletion
Number of subjects: 9
Study 37301885 — intervention group
Group type: COMPARATOR
Intervention: Neo-T therapy without lymphodepletion
Number of subjects: 9
Study 37301934 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 60
Study 37301934 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 60
Study 37301974 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate kangaroo mother care (iKMC)
Number of subjects: 5
Study 37301974 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 5
Study 37302039 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa intestinal gel (LCIG)
Number of subjects: 0
Study 37302134 — intervention group
Group type: EXPERIMENTAL
Intervention: MANTRa (24-34 individual sessions)
Number of subjects: 92
Study 37302134 — intervention group
Group type: COMPARATOR
Intervention: TAU-O (standard individual psychotherapy)
Number of subjects: 92
Study 37302348 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-morbid CVD/CVRF
Number of subjects: 10876
Study 37302348 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD/CVRF
Number of subjects: 10876
Study 37302348 — intervention group
Group type: EXPERIMENTAL
Intervention: Not receiving active cancer therapy
Number of subjects: 10876
Study 37302348 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 related cardiovascular complications
Number of subjects: 10876
Study 37302393 — intervention group
Group type: EXPERIMENTAL
Intervention: pyrotinib, trastuzumab, docetaxel, and carboplatin
Number of subjects: 69
Study 37302393 — intervention group
Group type: COMPARATOR
Intervention: placebo, trastuzumab, docetaxel, and carboplatin
Number of subjects: 69
Study 37302393 — intervention group
Group type: EXPERIMENTAL
Intervention: pyrotinib
Number of subjects: 69
Study 37302393 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 69
Study 37302406 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 1323
Study 37302406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1323
Study 37302449 — intervention group
Group type: EXPERIMENTAL
Intervention: CurQD (curcumin-QingDai) 3 g/d for 8 weeks
Number of subjects: 42
Study 37302449 — intervention group
Group type: EXPERIMENTAL
Intervention: CurQD (curcumin-QingDai) maintenance after 8 weeks
Number of subjects: 42
Study 37302449 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 42
Study 37302513 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathways to Freedom Video
Number of subjects: 1053
Study 37302513 — intervention group
Group type: COMPARATOR
Intervention: Standard Video
Number of subjects: 1053
Study 37302513 — intervention group
Group type: COMPARATOR
Intervention: Quitline Services Only
Number of subjects: 1053
Study 37302533 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin-assisted group therapy (25 mg high-dose session)
Number of subjects: 12
Study 37302544 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 37302573 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 90
Study 37302573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 37302651 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical myectomy
Number of subjects: 173
Study 37302712 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral treatment with ovalbumin (OVA) in obese mice
Number of subjects: 0
Study 37302712 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemia treatment in obese mice
Number of subjects: 0
Study 37302712 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with a hypoglycemic drug in obese mice
Number of subjects: 0
Study 37302712 — intervention group
Group type: COMPARATOR
Intervention: Comparison of serum IgE levels in individuals with T2D
Number of subjects: 0
Study 37302737 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation over 5 years
Number of subjects: 0
Study 37302737 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37302738 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant left atrial appendage (LAA) closure during open-heart surgery
Number of subjects: 0
Study 37302738 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LAA closure)
Number of subjects: 0
Study 37302963 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-dose esketamine-dexmedetomidine combination
Number of subjects: 200
Study 37302963 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled sufentanil analgesia (4 μg kg)
Number of subjects: 200
Study 37303003 — intervention group
Group type: EXPERIMENTAL
Intervention: BIA method for calculating CM dose
Number of subjects: 89
Study 37303003 — intervention group
Group type: COMPARATOR
Intervention: TBW method for calculating CM dose
Number of subjects: 89
Study 37303003 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean body weight using BIA
Number of subjects: 89
Study 37303003 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean body weight BIA protocol
Number of subjects: 89
Study 37303034 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab
Number of subjects: 751
Study 37303073 — intervention group
Group type: EXPERIMENTAL
Intervention: Pupillometry measures (PUAL and PLR)
Number of subjects: 313
Study 37303073 — intervention group
Group type: COMPARATOR
Intervention: Numeric Rating Scale (NRS) for self-reported pain intensity
Number of subjects: 313
Study 37303085 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 100
Study 37303085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 37303083 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers of Kidney Tubule Health, Injury, and Inflammation
Number of subjects: 0
Study 37303153 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical hippotherapy group (MHG)
Number of subjects: 30
Study 37303153 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 37303618 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality headset pain education and mindfulness intervention
Number of subjects: 20
Study 37303683 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus clopidogrel and rt-PA intravenous thrombolytic therapy
Number of subjects: 76
Study 37303683 — intervention group
Group type: COMPARATOR
Intervention: Aspirin plus clopidogrel
Number of subjects: 76
Study 37303805 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (TAF)
Number of subjects: 272
Study 37303805 — intervention group
Group type: COMPARATOR
Intervention: Entecavir (ETV)
Number of subjects: 272
Study 37304043 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 502
Study 37304043 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 2.0 mg
Number of subjects: 502
Study 37304043 — intervention group
Group type: COMPARATOR
Intervention: Benchmark linear model of baseline age and BCVA
Number of subjects: 502
Study 37304164 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial PRGS ≤ 2
Number of subjects: 97
Study 37304164 — intervention group
Group type: COMPARATOR
Intervention: Initial PRGS ≥ 3
Number of subjects: 97
Study 37304164 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological response (defined as lower or stable mean PRGS)
Number of subjects: 97
Study 37304164 — intervention group
Group type: COMPARATOR
Intervention: Progression (defined as increasing mean PRGS)
Number of subjects: 97
Study 37304207 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-Assisted Language Intervention (TALI)
Number of subjects: 0